Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Construction in Progress (2016 - 2017)

Immucell (ICCC) has disclosed Construction in Progress for 6 consecutive years, with $17.1 million as the latest value for Q3 2017.

  • For the quarter ending Q3 2017, Construction in Progress rose 1547.34% year-over-year to $17.1 million, compared with a TTM value of $17.1 million through Sep 2017, up 1547.34%, and an annual FY2016 reading of $3.7 million, up 240.53% over the prior year.
  • Construction in Progress was $17.1 million for Q3 2017 at Immucell, up from $13.3 million in the prior quarter.
  • Across five years, Construction in Progress topped out at $17.1 million in Q3 2017 and bottomed at $4137.0 in Q1 2013.
  • Average Construction in Progress over 5 years is $2.7 million, with a median of $588408.0 recorded in 2015.
  • The sharpest move saw Construction in Progress plummeted 96.47% in 2016, then skyrocketed 39796.98% in 2017.
  • Year by year, Construction in Progress stood at $9600.0 in 2013, then surged by 13136.17% to $1.3 million in 2014, then dropped by 14.62% to $1.1 million in 2015, then skyrocketed by 240.53% to $3.7 million in 2016, then soared by 363.16% to $17.1 million in 2017.
  • Business Quant data shows Construction in Progress for ICCC at $17.1 million in Q3 2017, $13.3 million in Q2 2017, and $7.5 million in Q1 2017.